3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
3
Stomach Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-Positive Primary Breast Cancer
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Paclitaxel
30
Carboplatin
24
Cisplatin
11
Topotecan
8
liposomal doxorubicin
6
Hyperthermic Intraperitoneal Chemotherapy
6
mirvetuximab soravtansine
5
Cyclophosphamide
5
Drug Therapy
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
rucaparib
3
Peripheral Blood Stem Cell Transplantation
3
Neoadjuvant Therapy
3
Doxorubicin
3
Docetaxel
3
CP protocol
3
olaparib
2
liposomal amphotericin B
2
Surgical Procedures, Operative
2
Letrozole
2
Gemcitabine
2
trebananib
1
trastuzumab deruxtecan
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
niraparib
1
fluzoparib
1
epothilone B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled